1. Home
  2. DTST vs APVO Comparison

DTST vs APVO Comparison

Compare DTST & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Data Storage Corporation

DTST

Data Storage Corporation

HOLD

Current Price

$3.96

Market Cap

8.5M

Sector

Technology

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.84

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTST
APVO
Founded
2001
2016
Country
United States
United States
Employees
55
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
8.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
DTST
APVO
Price
$3.96
$4.84
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.1K
34.4K
Earning Date
04-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
$25.39
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.25
$0.25
52 Week High
$5.44
$13.11

Technical Indicators

Market Signals
Indicator
DTST
APVO
Relative Strength Index (RSI) 47.75 48.51
Support Level $3.91 $3.88
Resistance Level $4.34 $5.69
Average True Range (ATR) 0.21 0.36
MACD 0.00 0.09
Stochastic Oscillator 21.31 58.05

Price Performance

Historical Comparison
DTST
APVO

About DTST Data Storage Corporation

Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: